Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, are pleased to announce the signing of a Memorandum of Understanding (MOU) to advance drug development for lysosomal diseases (LDs) and improve the quality of life for those impacted by these conditions.
The MOU outlines a strategic partnership aimed at leveraging both organizations’ strengths in genetic and real-world data (RWD) to overcome barriers in developing safe and effective therapies for LDs.
CENTOGENE is a global leader in genomic and multiomic testing services, utilizing advanced sequencing technologies to accelerate the diagnosis and development of treatments for rare and neurodegenerative diseases. Since 2006, CENTOGENE has generated data-driven insights from its Diagnostics segment – capturing the data in the CENTOGENE Biodatabank, the world’s largest real-world integrated multiomic data repository in rare and neurodegenerative diseases with over 850,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent.
C-Path forms collaborative work groups comprised of diverse stakeholders to identify specific barriers to developing safe and effective therapies for a given disease. These focus groups then create tools and solutions that help drug developers overcome those barriers. Established in 2023, under the executive leadership of Amanda Klein, Pharm.D., C-Path’s Critical Path for Lysosomal Diseases (CPLD) Consortium is a dynamic public-private partnership aimed at accelerating drug development for LDs.
The MOU defines the collaborative potential between C-Path and CENTOGENE, including:
- Data Enrichment and Linkage: Enhancing data enrichment and/or linkage for LDs, particularly in Niemann-Pick disease type C, Gaucher disease types 2 and 3, and mucopolysaccharidosis type II.
- Genetic Testing Services: Providing genetic testing services for clinical trials or observational studies.
- Sample Analysis Reporting: Offering sample analysis reporting services for diagnostics conducted by CENTOGENE or other labs via CentoCloud, using predefined NGS sequencing devices and library kits.
- Access to CENTOGENE Biodatabank: Allowing limited access to the CENTOGENE Biodatabank for analyzing patients from CPLD projects, which may or may not involve data linkage.
- Joint Cobranding Efforts: Promoting the uniqueness of the collaboration on both RWD and genetic data in LDs.
“At CENTOGENE, we are committed to delivering data-driven, life-changing answers to accelerate and de-risk drug discovery and development. Precision, advanced analysis, and access is where our Biodatabank makes a qualitative difference,” said Prof. Peter Bauer, M.D., Chief Medical and Genomic Officer at CENTOGENE. “In partnering with C-Path, we are advancing our shared vision of transforming real-world data into life-saving therapeutics for patients around the world.”
Krista Casazza, Ph.D., CPLD Scientific Director, added, “This partnership with CENTOGENE will enable us to combine our expertise and resources to overcome significant barriers in LD research and drug development.”
SOURCE: GlobeNewswire